<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ethosuximide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ethosuximide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ethosuximide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12454" href="/d/html/12454.html" rel="external">see "Ethosuximide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13288" href="/d/html/13288.html" rel="external">see "Ethosuximide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F168739"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zarontin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866837"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Zarontin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F168781"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiseizure Agent, Succinimide</li></ul></div>
<div class="block doa drugH1Div" id="F168743"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61bda58a-f301-41ea-9d71-83d6dddd4ec7">Absence seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Absence (petit mal) seizures: Oral:</b> Initial: 500 mg/day. Individualize dose based on patient response by increasing in small increments (eg, ≤250 mg); doses &gt;1.5 g/day, in divided doses, should only be used under the strict supervision of a physician; higher doses may be necessary in some patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Single daily doses have been shown to be effective and well tolerated in clinical trials (in children) and pharmacokinetic analysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-816588','lexi-content-ref-641778','lexi-content-ref-25470190']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-816588','lexi-content-ref-641778','lexi-content-ref-25470190'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991199"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with extreme caution. </p></div>
<div class="block doha drugH1Div" id="F50988379"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with extreme caution. </p></div>
<div class="block doe drugH1Div" id="F168744"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F168763"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13288" href="/d/html/13288.html" rel="external">see "Ethosuximide: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61bda58a-f301-41ea-9d71-83d6dddd4ec7">Absence seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Absence seizures: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Ethosuximide monotherapy or valproic acid monotherapy is considered an appropriate initial therapy for the treatment of absence seizures of childhood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29898971','lexi-content-ref-25340221']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29898971','lexi-content-ref-25340221'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2.5 to &lt;3 years: Limited data available: Oral: Initial: 10 mg/kg/day in 2 or 3 divided doses, titrate to response in 5 to 10 mg/kg/day increments every 7 days; the reported mean daily dose was 33.5 ± 15.3 mg/kg/day in 2 to 3 divided doses in a population that included 155 subjects 2.5 to 13 years of age (39 patients were &lt;6 years of age); reported maximum daily dose: 60 mg/kg/<b>day</b> or 2,000 mg/<b>day</b> in divided doses, whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20200390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20200390'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 3 to &lt;6 years: Oral: Initial: 10 mg/kg/day in 2 or 3 divided doses, titrate to response in 5 to 10 mg/kg/day increments every 7 days; manufacturer labeling suggests an initial dose of 250 mg/day in 2 or 3 divided doses; titrate dose in small increments (eg, ≤250 mg) every 4 to 7 days to clinical response; usual daily dose range: 20 to 30 mg/kg/day in 2 to 3 divided doses; in a population that included 155 subjects 2.5 to 13 years of age (39 patients were &lt;6 years of age), the reported mean daily dose was 33.5 ± 15.3 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20200390','lexi-content-ref-Kliegman.1','lexi-content-ref-Pellock.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20200390','lexi-content-ref-Kliegman.1','lexi-content-ref-Pellock.1','lexi-content-ref-manu.1'])">Ref</a></span>); the maximum reported dose was 60 mg/kg/<b>day</b> or 2,000 mg<b>/day </b>in divided doses, whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20200390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20200390'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: Initial: 10 mg/kg/day in 2 or 3 divided doses, titrate to response in 5 to 10 mg/kg/day increments every 7 days; manufacturer labeling suggests an initial dose of 500 mg/day in 2 or 3 divided doses; titrate dose in small increments (eg, 250 mg) every 4 to 7 days to clinical response; usual daily dose: 20 to 30 mg/kg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20200390','lexi-content-ref-Kliegman.1','lexi-content-ref-Pellock.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20200390','lexi-content-ref-Kliegman.1','lexi-content-ref-Pellock.1','lexi-content-ref-manu.1'])">Ref</a></span>); in trials, the maximum reported dose was 60 mg/kg/<b>day</b> or 2,000 mg/<b>day </b>in divided doses<b>,</b> whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20200390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20200390'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109883"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with extreme caution.</p></div>
<div class="block dohp drugH1Div" id="F51109884"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; use with extreme caution.</p></div>
<div class="block adr drugH1Div" id="F168710"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritic erythematous rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hirsutism, increased libido, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, abdominal pain, anorexia, diarrhea, epigastric pain, gastric distress, gingival hyperplasia, hiccups, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Microscopic hematuria, vaginal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, leukopenia, pancytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug rash with eosinophilia and systemic symptoms, hypersensitivity reaction, swollen tongue</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, ataxia, delusional paranoid disorder, depression, dizziness, drowsiness, euphoria, fatigue, headache, hyperactive behavior, irritability, lack of concentration, lethargy, night terrors, sleep disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Myopia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome (Matos 2021), toxic epidermal necrolysis (Matos 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Imai 2003), immune thrombocytopenia (Shatara 2019), lymphadenopathy (Ojinnaka 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (Coulter 1983)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Acute mania (Chien 2011), psychotic symptoms (Chien 2011), suicidal ideation (Chien 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Systemic lupus erythematosus (Crespel 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal function test abnormality</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Oropharyngeal edema (Shang 2021)</p></div>
<div class="block coi drugH1Div" id="F168725"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ethosuximide, succinimides, or any component of the formulation. </p></div>
<div class="block war drugH1Div" id="F168707"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood dyscrasias: Severe blood dyscrasias (some fatal) have been reported. Monitor CBC, especially if signs/symptoms of infection develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Severe reactions, including Stevens-Johnson syndrome (SJS), have been reported with an onset usually within 28 days, but may be observed later. Drug should be discontinued if there are any signs of rash, unless the rash is clearly not drug-related. If SJS is suspected do not resume ethosuximide and consider alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Drug-induced immune thrombocytopenia: Drug-induced immune thrombocytopenia (DITP) has been reported; may occur 1 to 3 weeks after initiation. Discontinue use and treat appropriately if DITP is suspected. Avoid use in patients with a history of ethosuximide-induced immune thrombocytopenia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Changes in hepatic function have been reported; monitor LFTs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiorgan hypersensitivity reactions: Potentially serious, sometimes fatal drug reaction with eosinophilia and systemic symptoms (DRESS), also known as multiorgan hypersensitivity reactions, have been reported. Monitor for signs and symptoms (eg, fever, rash, exfoliative dermatitis, lymphadenopathy, facial swelling, eosinophilia) in association with other organ system involvement (eg, hepatitis, nephritis, hematologic abnormalities, pneumonitis, myocarditis, myositis, pericarditis). If DRESS is suspected, discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal effects: Changes in renal function have been reported; monitor during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic lupus erythematous: Cases of systemic lupus erythematosus (SLE) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation: Pooled analysis of trials involving various antiseizure medications (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials ≤24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with extreme caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with extreme caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure medications should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>
<div class="block foc drugH1Div" id="F168718"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zarontin: 250 mg [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zarontin: 250 mg/5 mL (474 mL [DSC]) [contains fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow), saccharin sodium, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zarontin: 250 mg/5 mL (474 mL) [contains fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #6 (sunset yellow), saccharin sodium, sodium benzoate; raspberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/5 mL (473 mL, 474 mL)</p></div>
<div class="block geq drugH1Div" id="F168703"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F168727"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Ethosuximide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $2.14 - $2.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Zarontin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $1.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ethosuximide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (per mL): $0.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Zarontin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (per mL): $0.35</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866838"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zarontin: 250 mg [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zarontin: 250 mg/5 mL (500 mL) [contains alcohol, usp, fd&amp;c yellow #6 (sunset yellow), saccharin sodium, sodium benzoate]</p></div>
<div class="block adm drugH1Div" id="F56563430"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral: </b>Administer with food or milk to decrease GI upset.</p></div>
<div class="block admp drugH1Div" id="F52612777"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food or milk to decrease GI upset.</p></div>
<div class="block meg drugH1Div" id="F10881925"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2012%2F012380s034mg.pdf&amp;token=0bX%2FYftcPr3bY66LI02YUKYcuIfgl2pEYMPkhFGEMGYn7zZSEzLH5Pr56cl50%2B%2FBC3Xx7oD2vgte%2FdJWlR0DEBbVFhll1AZH8LdNHR9521Y%3D&amp;TOPIC_ID=9440" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/012380s034mg.pdf</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F168721"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Absence (petit mal) seizures</b>: Management of absence (petit mal) seizures</p></div>
<div class="block mst drugH1Div" id="F168786"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ethosuximide may be confused with ethionamide, methsuximide.</p>
<p style="text-indent:-2em;margin-left:4em;">Zarontin may be confused with Neurontin, Xalatan, Zantac, Zaroxolyn.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F168776"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F168712"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Ethosuximide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ethosuximide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Ethosuximide may increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Ethosuximide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Antiseizure Agents. Mefloquine may decrease the serum concentration of Antiseizure Agents. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If antiseizure drugs are being used for another indication, monitor antiseizure drug concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiseizure Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Ethosuximide may decrease the serum concentration of Valproate Products. Valproate Products may increase the serum concentration of Ethosuximide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54124392"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients with epilepsy who are planning to become pregnant in advance should have baseline serum concentrations measured once or twice prior to pregnancy during a period when seizure control is optimal (Patsalos 2008; Patsalos 2018).</p></div>
<div class="block pri drugH1Div" id="F3445821"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ethosuximide crosses the placenta. Birth defects have been reported in infants. Epilepsy itself, the number of medications, genetic factors, or a combination of these may influence the teratogenicity of antiseizure therapy. In general, polytherapy may increase the risk of congenital malformations; monotherapy with the lowest effective dose is recommended (Harden 2009). Monitoring of serum concentrations should begin prior to pregnancy and continue up to once a month during pregnancy in patients with stable seizure control (Patsalos 2008; Patsalos 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Patients exposed to ethosuximide during pregnancy are encouraged to enroll themselves into the NAAED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.</p></div>
<div class="block brc drugH1Div" id="F20688469"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Ethosuximide is present in breast milk. The manufacturer recommends that caution be exercised when administering ethosuximide to breastfeeding patients. The Canadian label recommends against breastfeeding while taking ethosuximide.</p></div>
<div class="block mop drugH1Div" id="F168716"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum concentrations, CBC, platelets, liver enzymes (periodic), urinalysis (periodic); serial platelet counts and presence of drug-dependent antiplatelet antibodies (if possible) in patients with suspected drug-induced immune thrombocytopenia; signs of rash; suicidality (eg, suicidal thoughts, depression, behavioral changes).</p></div>
<div class="block rer drugH1Div" id="F3445868"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Therapeutic: 40 to 100 mcg/mL; levels up to 150 mcg/mL have been reported without toxicity</p></div>
<div class="block pha drugH1Div" id="F168706"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Increases the seizure threshold and suppresses paroxysmal spike-and-wave pattern in absence seizures; depresses nerve transmission in the motor cortex</p></div>
<div class="block phk drugH1Div" id="F168724"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Complete and rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.7 L/kg (Battino 1995).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 21.8% (Patsalos 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A to &gt;40% inactive glucuronide conjugates (Patsalos 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination, serum: Children: 30 hours; Adults: 50 to 60 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 1 to 7 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine, slowly (12% to 20% as unchanged drug).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F168729"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ethosuximid neuraxpharm | Petinimid | Suxinutin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Serontin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Petinimid | Petnidan | Suxilep</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Etoxin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Suxinutin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Zartalin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Petinimid | Petnidan | Suxilep | Suxinutin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ethosuximid fairmed | Ethosuximid neuraxpharm | Petnidan | Suxinutin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Petnidan | Suxilep | Suxinutin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ethoxa</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Etosuximida | Zarontin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Etomal | Suxinutin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Petinimid | Zarontin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Emeside | Epesri | Ethosuximide aristo | Ethosuximide neuraxpharm | Zarontin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Petinimid | Zarontin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Petnidan | Suxilep | Suxinutin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Absenz</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Emeside | Epileo petit mal | Zarontin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Emeside | Zaronti | Zarontil | Zarontin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Absenz | Petinimid | Petnidan | Suxilep | Zarontin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ethosuximid neuraxpharm | Petinimid | Petnidan | Suxilep | Zarontin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Fluozoid</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ethymal | Zarontin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ethosuximide orifarm | Petnidan | Zarondan | Zarontin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Petinimid | Ronton | Suxilep | Suxinutin | Zarontin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Etosuximida | Zarontin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Suxinutin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ethosuximide native | Petnidan | Suxilep | Zarontin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ethosuximide orifarm | Etosuximid | Etosuximid 2care4 | Etosuximid abboxia | Etosuximid ebb | Etosuximid Medartuum | Suxinutin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Asamid | Petinimid | Petnidan | Suxinutin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Petinimid | Petnidan | Suxilep</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Petimid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Suxilep</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Zarontin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8549027">
<a name="8549027"></a>Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. <i>Clin Pharmacokinet</i>. 1995;29(4):257-286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/8549027/pubmed" id="8549027" target="_blank">8549027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-816588">
<a name="816588"></a>Buchanan RA, Kinkel AW, Turner JL, Heffelfinger JC. Ethosuximide dosage regimens. <i>Clin Pharmacol Ther</i>. 1976;19(2):143-147.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/816588/pubmed" id="816588" target="_blank">816588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21689989">
<a name="21689989"></a>Chien J. Ethosuximide-induced mania in a 10-year-old boy. <i>Epilepsy Behav</i>. 2011;21(4):483-485. doi:10.1016/j.yebeh.2011.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/21689989/pubmed" id="21689989" target="_blank">21689989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-641778">
<a name="641778"></a>Colburn WA, Gibaldi M. Use of MULTDOS for pharmacokinetic analysis of ethosuximide data during repetitive administration of single or divided daily doses. <i>J Pharm Sci</i>. 1978;67(4):574-575.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/641778/pubmed" id="641778" target="_blank">641778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6847455">
<a name="6847455"></a>Coulter DL. Ethosuximide-induced liver dysfunction. <i>Arch Neurol</i>. 1983;40(6):393-394. doi:10.1001/archneur.1983.04050060093029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/6847455/pubmed" id="6847455" target="_blank">6847455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19682032">
<a name="19682032"></a>Crespel A, Velizarova R, Agullo M, Gélisse P. Ethosuximide-induced de novo systemic lupus erythematosus with anti-double-strand DNA antibodies: a case report with definite evidence. <i>Epilepsia</i>. 2009;50(8):2003. doi:10.1111/j.1528-1167.2009.02144.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/19682032/pubmed" id="19682032" target="_blank">19682032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20200390">
<a name="20200390"></a>Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. <i>N Engl J Med</i>. 2010;362(9):790-799.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/20200390/pubmed" id="20200390" target="_blank">20200390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19398681">
<a name="19398681"></a>Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. <i>Neurology</i>. 2009;73(2):133-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/19398681/pubmed" id="19398681" target="_blank">19398681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13129598">
<a name="13129598"></a>Imai T, Okada H, Nanba M, Kawada K, Kusaka T, Itoh S. Ethosuximide induced agranulocytosis. <i>Brain Dev</i>. 2003;25(7):522-524. doi:10.1016/s0387-7604(03)00060-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/13129598/pubmed" id="13129598" target="_blank">13129598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29898971">
<a name="29898971"></a>Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. <i>Neurology</i>. 2018;91(2):74-81. doi:10.1212/WNL.0000000000005755<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/29898971/pubmed" id="29898971" target="_blank">29898971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34218457">
<a name="34218457"></a>Matos AL, Carvalho J, Calado R, Gomes T, Ramos L, Gonçalo M. Ethosuximide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap confirmed by patch testing in a child. <i>Contact Dermatitis</i>. 2021;85(5):602-604. doi:10.1111/cod.13928<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/34218457/pubmed" id="34218457" target="_blank">34218457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25340221">
<a name="25340221"></a>National Clinical Guideline Centre (UK). <i>The Epilepsies: The Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care</i>. London: Royal College of Physicians (UK); January 2012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/25340221/pubmed" id="25340221" target="_blank">25340221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11961853">
<a name="11961853"></a>Ojinnaka NC, Iloeje SO. Ethosuximide induced lymphadenopathy--a case report. <i>Cent Afr J Med</i>. 2001;47(1):18-19. doi:10.4314/cajm.v47i1.8586<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/11961853/pubmed" id="11961853" target="_blank">11961853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18397299">
<a name="18397299"></a>Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i>. 2008;49(7):1239-1276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/18397299/pubmed" id="18397299" target="_blank">18397299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29957667">
<a name="29957667"></a>Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. <i>Ther Drug Monit</i>. 2018;40(5):526-548. doi: 10.1097/FTD.0000000000000546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/29957667/pubmed" id="29957667" target="_blank">29957667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28542801">
<a name="28542801"></a>Patsalos PN, Zugman M, Lake C, et al. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations. <i>Epilepsia</i>. 2017;58:1234–1243. doi: 10.1111/epi.13802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/28542801/pubmed" id="28542801" target="_blank">28542801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pellock.1">
<a name="Pellock.1"></a>Pellock JM, Bourgeois BFD, Dodson WE, eds. <i>Pediatric Epilepsy</i>. 3rd ed. New York NY: Demos Medical Publishing; 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33218689">
<a name="33218689"></a>Shang H, Glaun M, Ongkasuwan J. Ethosuximide induced macroglossia and oropharyngeal edema. <i>Int J Pediatr Otorhinolaryngol</i>. 2021;140:110498. doi:10.1016/j.ijporl.2020.110498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/33218689/pubmed" id="33218689" target="_blank">33218689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30212418">
<a name="30212418"></a>Shatara M, Regling K, Sabo C, Figueroa M, Taub JW, Rajpurkar M. Ethosuximide-induced thrombocytopenia: a case report. <i>J Pediatr Hematol Oncol</i>. 2019;41(5):420-421. doi:10.1097/MPH.0000000000001310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/30212418/pubmed" id="30212418" target="_blank">30212418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25470190">
<a name="25470190"></a>Vajda FJ, Eadie MJ. The clinical pharmacology of traditional antiepileptic drugs. <i>Epileptic Disord</i>. 2014;16(4):395-408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ethosuximide-drug-information/abstract-text/25470190/pubmed" id="25470190" target="_blank">25470190</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Zarontin (ethosuximide) [product monograph]. Montreal, Quebec, Canada: ERFA Canada Inc; March 2013.</div>
</li>
<li>
<div class="reference">
                  Zarontin capsule (ethosuximide, USP) [prescribing information]. New York, NY: Pfizer; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zarontin.1">
<a name="Zarontin.1"></a>Zarontin oral solution (ethosuximide) [prescribing information]. New York, NY: Parke-Davis; March 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9440 Version 371.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
